Capricor Sues Japanese Partner Over Botched Duchenne Therapy Launch, Alleges Pricing Barriers

Capricor Therapeutics has filed a lawsuit against Nippon Shinyaku and its subsidiary NS Pharma, accusing the Japanese partners of sabotaging the commercial launch of deramiocel, the biotech's closely watched cell therapy for Duchenne muscular dystrophy. The legal action, filed in what appears to be a U.S. jurisdiction, centers on allegations that the companies failed to execute adequate launch preparations, while simultaneously structuring pricing in a way that could render the treatment financially out of reach for a significant portion of patients who need it.

The dispute represents a rare public breakdown in biotech partnership relations, particularly in the rare disease space where commercial infrastructure and patient access are critical to a therapy's success. Deramiocel has attracted regulatory and investor attention as a potential treatment for a devastating progressive muscle-wasting condition that primarily affects young boys. Sources familiar with the matter suggest Capricor had relied on Nippon Shinyaku's regional market expertise and distribution capabilities, leaving the biotech with limited leverage as launch timelines slipped.

The case raises broader questions about accountability in biotech co-development agreements, especially when commercialization responsibilities are delegated to regional partners with different market incentives. Industry observers note that pricing disputes rarely escalate to litigation this early in a product lifecycle, signaling either a fundamental breakdown in communication or a deliberate strategy by Capricor to force a resolution before patient access is further compromised. The outcome could set precedent for how similar disputes over rare disease therapy access are handled across international partnerships.